1. Home
  2. NMFC vs IRWD Comparison

NMFC vs IRWD Comparison

Compare NMFC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Mountain Finance Corporation

NMFC

New Mountain Finance Corporation

HOLD

Current Price

$7.16

Market Cap

745.2M

Sector

Finance

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.57

Market Cap

663.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMFC
IRWD
Founded
2010
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
745.2M
663.6M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
NMFC
IRWD
Price
$7.16
$3.57
Analyst Decision
Hold
Buy
Analyst Count
4
3
Target Price
$8.63
$7.67
AVG Volume (30 Days)
480.0K
2.0M
Earning Date
05-04-2026
05-11-2026
Dividend Yield
15.27%
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.24
Revenue
N/A
$298,276,000.00
Revenue This Year
N/A
$57.95
Revenue Next Year
N/A
$4.39
P/E Ratio
$12.51
$14.73
Revenue Growth
N/A
8.88
52 Week Low
$7.29
$0.66
52 Week High
$10.90
$5.78

Technical Indicators

Market Signals
Indicator
NMFC
IRWD
Relative Strength Index (RSI) 26.88 48.48
Support Level N/A $3.08
Resistance Level $8.17 $3.95
Average True Range (ATR) 0.19 0.19
MACD -0.07 0.04
Stochastic Oscillator 4.28 67.44

Price Performance

Historical Comparison
NMFC
IRWD

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: